Coherus Oncology, Inc.

Ladies and gentlemen, thank you for standing by, and welcome to the Coherus Biosciences 2019 Third Quarter Earnings Conference Call. My name is Julianne, and I will be your conference operator for the call today. At this time, all participants are in a listen-only mode. And as a reminder, this conference call is being recorded. I would now like to turn the call over to David Arrington, Vice President of Investment Relations and Corporate Affairs. Please go ahead, sir.

Thank you, Julianne, and good afternoon, everyone. After close of market today, we issued a press release on the third quarter financial results. This release can be found on the Coherus Biosciences website. Joining me for today's call will be Denny Lanfear, Coherus CEO, Dr. Jean Bourret, Chief Financial Officer, Jim Hazard, SVP of Commercial, Thomas Fitzpatrick, Chief Legal Officer. Before we begin our formal remarks, I would like to remind you that we will be making forward-looking statements with respect to product development plans, all of which involve certain assumptions, risks, and uncertainties that are beyond our control and could cause actual results to differ from these statements. A description of these risks can be found on our most recent filings with the SEC. In addition, Coherus Biosciences does not undertake any obligation to update any forward-looking statements made during this call. I will now turn the call over to Denny.

Thank you, David, and welcome, everyone, to our Q3 earnings call. Today, we'll cover four broad areas for you. First, we'll review for you the Q3 2019 Udenica results, which saw the company achieve a 20% unit market share one-quarter head of guidance, and we expect to see additional growth in Q4. Secondly, we'll discuss our ophthalmology licensing agreement that we announced today, which signals the initiation of the commercial phase of our ophthalmology franchise in preparation for a 2021 launch. With respect to that, we will provide the rationale and benefits of the agreement, and further, we will describe the similarities between ophthalmology and oncology markets, and why we believe these two therapeutic areas are synergistic with respect to our existing commercial infrastructure. I have with me today our CSPB of commercial, Mr. Jim Hazard, who will walk you through the commercial case in ophthalmology and provide some additional color. Third, we'll make some remarks regarding the company's inflammation portfolio and CHS 1420, our Humira bow similar. After that, we'll turn the call over to our Chief Financial Officer, Dr. Jean Barre, who will review our quarterly and year-to-date financial performance. And then lastly, we will provide you with a key takeaway summary before, of course, going to the Q&A. Now, I'll let Mr. Hazard review for you the Udenica progress in Q3. Jim?